Terms like active surveillance and watchful waiting are confusing. They are not the same. And, who should use either of these strategies when confronted with a prostate cancer diagnosis? The US Prostate Cancer Foundation provides a quick explanation of the crucial medical characteristics that guide that decision. The article starts below, and use the embedded link to read further.
The Institute for Cancer Research in the United Kingdom is conducting research using gene tests to identify which patients will benefit from PSMA targeting therapies such as Lutetium 177. So called “search and destroy’ targeting uses Prostate Specific Membrane Antigen to locate individual cancer cells and deliver a lethal dose of radiation. However, the effectiveness of the treatment varies.
To learn more learn more about why such gene testing is needed and how PSMA works read on: https://www.pcf.org/news/gene-test-picks-out-prostate-cancer-patients-who-could-benefit-from-search-and-destroy-medicine/?utm_source=NewsPulse&utm_medium=email&utm_campaign=AUG19NP
Following the 2018 Nobel Prize for work in cancer treatments using immunotherapy to a Japanese and American researcher, the British paper The Guardian explains the effective immuno-therapies already in place and how some newer promising approaches work.